Literature DB >> 34141076

Benzo[d]thiazol-5-yl Compounds as O-GlcNAcase Inhibitors for Treating Alzheimer's Disease.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34141076      PMCID： PMC8201512          DOI： 10.1021/acsmedchemlett.1c00259

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Therapies for Alzheimer's disease: a metabolic perspective.

Authors:  Raquel Domingues; Claúdia Pereira; Maria Teresa Cruz; Ana Silva
Journal:  Mol Genet Metab       Date:  2021-01-27       Impact factor: 4.797

Review 2.  O-GlcNAcase: Emerging Mechanism, Substrate Recognition and Small-Molecule Inhibitors.

Authors:  Ahmed A Elbatrawy; Eun Ju Kim; Ghilsoo Nam
Journal:  ChemMedChem       Date:  2020-06-16       Impact factor: 3.466

Review 3.  Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.

Authors:  Lisha Wang; Rajnish Kumar; Pavel F Pavlov; Bengt Winblad
Journal:  Eur J Med Chem       Date:  2020-10-15       Impact factor: 6.514

Review 4.  Monitoring and modulating O-GlcNAcylation: assays and inhibitors of O-GlcNAc processing enzymes.

Authors:  Matthew G Alteen; Hong Yee Tan; David J Vocadlo
Journal:  Curr Opin Struct Biol       Date:  2021-01-31       Impact factor: 6.809

Review 5.  Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.

Authors:  Songzhe He; Fushun Wang; Ken Kin Lam Yung; Shiqing Zhang; Shaogang Qu
Journal:  ACS Chem Neurosci       Date:  2021-03-26       Impact factor: 4.418

Review 6.  Targeting tau: Clinical trials and novel therapeutic approaches.

Authors:  Lawren VandeVrede; Adam L Boxer; Manuela Polydoro
Journal:  Neurosci Lett       Date:  2020-05-04       Impact factor: 3.197
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.